“…Also, the P248L variant is associated with some residual GCDH activity in other patients. In addition, in the p.Val400Met homozygous mutation study, riboflavin was reported to be a driving force for the mutant enzyme [ 23 ]. These results provide principal proof for the beneficial effects of riboflavin in GA-I.…”